AMD3100

DRUG11 trials

Conditions

Acute Myelogenous LeukemiaFanconi AnemiaHead and Neck CancerHealthy VolunteersHematologic NeoplasmsHodgkin DiseaseInfertility of Uterine OriginLeukemia, Lymphoblastic, Acute

Phase 1

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

CompletedNCT00241358

Washington University School of MedicineHodgkin Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Chronic +5

Start: 2004-05-31End: 2010-02-28Updated: 2017-06-06

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

CompletedNCT00322127

National Heart, Lung, and Blood Institute (NHLBI)Healthy Volunteers

Start: 2006-06-14End: 2015-01-23Updated: 2020-10-08

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

WithdrawnNCT00396968

Genzyme, a Sanofi CompanyAcute Myelogenous Leukemia, Myelodysplastic Syndromes

Updated: 2014-02-11

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100

CompletedNCT00479115

Children's Hospital Medical Center, CincinnatiFanconi Anemia

Start: 2007-05-31End: 2010-12-31Updated: 2020-10-30

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

CompletedNCT00512252

Washington University School of MedicineLeukemia, Myeloid, Acute

Start: 2007-07-31End: 2010-06-30Updated: 2016-12-12

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

CompletedNCT00733824

Washington University School of MedicineHodgkin Disease, Lymphoma, Non-Hodgkin

Start: 2008-11-30End: 2013-09-30Updated: 2017-03-09

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

CompletedNCT01026987

Washington University School of MedicineStem Cell Transplant Patients

Start: 2010-04-29End: 2016-06-08Updated: 2017-01-25

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia

TerminatedNCT01655875

Emory UniversityPediatric Acute Lymphoblastic Leukemia, Relapsed, Pediatric Acute Myeloblastic Leukemia, Relapsed

Start: 2012-06-30End: 2014-04-30Updated: 2014-04-07

Phase 2

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

CompletedNCT00914849

Washington University School of MedicineHematologic Neoplasms

Start: 2009-08-31End: 2012-02-29Updated: 2017-05-17

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

WithdrawnNCT04058145

Massachusetts General HospitalHead and Neck Cancer

Start: 2019-09-30End: 2019-10-11Updated: 2020-09-07

Unknown Phase

Endometrial Rejuvenation Study

TerminatedNCT04045821

Reproductive Medicine Associates of New JerseyInfertility of Uterine Origin

Start: 2020-01-17End: 2021-05-04Updated: 2021-05-19

Related Papers

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Nature Medicine2023-04-0167 citations

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Blood2017-03-1478 citations

Effect of high-dose plerixafor on CD34 <sup>+</sup> cell mobilization in healthy stem cell donors: results of a randomized crossover trial

Haematologica2016-10-2052 citations

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

2008-04-21239 citations